BioLineRx Announces Q3 EPS of 0c, Unchanged from Last Year
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 24 2025
0mins
Should l Buy BLRX?
Q3 Revenue Decline: BioLineRx reported a Q3 revenue of $427k, a significant drop from $4.121M in the same period last year.
Joint Venture Announcement: The company established a joint venture with Hemispherian to expand its cancer treatment pipeline, focusing on glioblastoma alongside its ongoing PDAC program.
GLIX1 Development: Hemispherian's lead asset, GLIX1, targets DNA repair mechanisms in cancer cells and has shown strong efficacy in pre-clinical models.
Upcoming Clinical Trials: BioLineRx plans to initiate a Phase 1/2a first-in-human study for GLIX1 in Q1 of next year while continuing pre-clinical activities for potential trials in other cancers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BLRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BLRX
Wall Street analysts forecast BLRX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.420
Low
12.00
Averages
12.00
High
12.00
Current: 2.420
Low
12.00
Averages
12.00
High
12.00
About BLRX
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioLineRx Reports FY EPS Beat Despite Revenue Plunge
- Earnings Beat: BioLineRx's FY report reveals a GAAP EPS of $0.00, exceeding expectations by $0.68, although this figure does not reflect the overall financial health of the company.
- Revenue Decline: The company reported revenue of $1.18 million, a staggering 95.9% year-over-year decrease, missing expectations by $0.3 million, indicating significant operational challenges.
- Cash Position: With $20.9 million on its balance sheet as of December 31, 2025, BioLineRx is projected to maintain its cash runway into the first half of 2027, suggesting short-term survival capability.
- Market Reaction: Despite the EPS beat, the sharp revenue decline may negatively impact investor confidence, highlighting the company's vulnerability in a competitive market.
See More
BIOLINE RX LTD SET TO LAUNCH PHASE 1/2A CLINICAL TRIAL OF GLIX1 FOR GLIOBLASTOMA TREATMENT BY MONTH'S END
Clinical Trial Announcement: BioLineRx Ltd has initiated Phase 1/2 clinical trials for GLIX1, a treatment aimed at addressing glioblastoma.
Timeline for Results: The company expects to have results from the trial by the end of this month.
See More
BioLineRx Initiates GLIX1 Clinical Trial for Glioblastoma
- Clinical Trial Launch: BioLineRx is set to initiate its Phase 1/2a clinical trial of GLIX1 for glioblastoma by the end of this month, aiming to address unmet needs in cancer treatment, thereby enhancing the company's strategic positioning in oncology.
- Innovative Drug Mechanism: GLIX1 targets DNA damage response mechanisms, demonstrating significant efficacy in numerous pre-clinical models and a favorable safety profile in toxicology studies, which lays a solid foundation for its clinical application success.
- Market Opportunity: Patient enrollment in the ongoing CheMo4METPANC Phase 2b clinical trial for metastatic pancreatic cancer has accelerated, with BioLineRx anticipating an interim analysis in 2026, further validating its therapeutic potential in high-need tumor types and creating sustained value for the company.
- Financial Update: BioLineRx's 2025 fiscal year report indicates ongoing losses; however, the company is enhancing financial flexibility through capital financing and equity issuance, providing necessary funding for the development of GLIX1 and other candidates, ensuring continued growth in the competitive biopharmaceutical market.
See More
BioLineRx to Initiate GLIX1 Clinical Trial for Glioblastoma
- Clinical Trial Progress: BioLineRx is on track to initiate a Phase 1/2a clinical trial of GLIX1 for glioblastoma by the end of this month, targeting DNA damage response mechanisms, which could address unmet needs in cancer treatment and enhance the company's competitive edge in oncology.
- Enhanced Patent Protection: The company has received a Notice of Allowance from the USPTO for a key patent covering GLIX1 in 90% of cancer types, ensuring its development beyond glioblastoma and strengthening its market position, with patent protection expected to last until 2040.
- Strong Financial Position: As of December 31, 2025, BioLineRx reported $20.9 million in cash and cash equivalents, sufficient to fund operations into the first half of 2027, indicating robust financial health that supports ongoing R&D initiatives.
- Accelerated Collaborative Research: Enrollment in the CheMo4METPANC Phase 2b clinical trial for metastatic pancreatic cancer has accelerated, with an interim analysis expected in 2026, reflecting the company's proactive approach in developing new treatment options for patients in need.
See More
BioLineRx to Announce FY Earnings on March 23
- Earnings Announcement Date: BioLineRx is set to release its financial results on March 23 before the market opens, with investors keenly awaiting performance metrics to gauge the company's future growth potential.
- Expected Financial Metrics: The consensus estimates project an EPS of -$0.77 and revenue of $1.48 million, which will provide critical insights into the company's financial health.
- Historical Performance Review: Over the past two years, BioLineRx has only beaten EPS estimates 25% of the time and revenue estimates 50% of the time, indicating uncertainty in the company's financial performance.
- Market Reaction Expectations: Investor reactions to the upcoming earnings report will directly influence BioLineRx's stock price movements, particularly given the company's historical performance has not consistently exceeded expectations.
See More
BioLineRx to Release Financial Results on March 23, 2026
- Earnings Release Schedule: BioLineRx will announce its audited financial results for the year ending December 31, 2025, on March 23, 2026, before U.S. markets open, providing investors with crucial insights into the company's financial health.
- Conference Call Details: The company will host a conference call at 8:30 a.m. EDT, featuring remarks from CEO Philip Serlin, allowing investors to engage directly with management through dial-in options at +1-888-281-1167 (U.S.) or +972-3-918-0685 (international).
- Clinical Trial Progress: BioLineRx's lead development asset, GLIX1, is expected to initiate a Phase 1/2a clinical trial in Q1 2026, targeting DNA damage response in glioblastoma and other solid tumors, showcasing the company's ongoing innovation in oncology treatments.
- Product Commercialization Status: The company's first approved product, APHEXDA® (motixafortide), is indicated for stem cell mobilization in multiple myeloma in the U.S. and is being commercialized globally by Ayrmid Ltd., indicating the company's gradual market expansion and collaboration potential.
See More
BioLineRx Reports FY EPS Beat Despite Revenue Plunge
- Earnings Beat: BioLineRx's FY report reveals a GAAP EPS of $0.00, exceeding expectations by $0.68, although this figure does not reflect the overall financial health of the company.
- Revenue Decline: The company reported revenue of $1.18 million, a staggering 95.9% year-over-year decrease, missing expectations by $0.3 million, indicating significant operational challenges.
- Cash Position: With $20.9 million on its balance sheet as of December 31, 2025, BioLineRx is projected to maintain its cash runway into the first half of 2027, suggesting short-term survival capability.
- Market Reaction: Despite the EPS beat, the sharp revenue decline may negatively impact investor confidence, highlighting the company's vulnerability in a competitive market.
See More
BIOLINE RX LTD SET TO LAUNCH PHASE 1/2A CLINICAL TRIAL OF GLIX1 FOR GLIOBLASTOMA TREATMENT BY MONTH'S END
Clinical Trial Announcement: BioLineRx Ltd has initiated Phase 1/2 clinical trials for GLIX1, a treatment aimed at addressing glioblastoma.
Timeline for Results: The company expects to have results from the trial by the end of this month.
See More
BioLineRx Initiates GLIX1 Clinical Trial for Glioblastoma
- Clinical Trial Launch: BioLineRx is set to initiate its Phase 1/2a clinical trial of GLIX1 for glioblastoma by the end of this month, aiming to address unmet needs in cancer treatment, thereby enhancing the company's strategic positioning in oncology.
- Innovative Drug Mechanism: GLIX1 targets DNA damage response mechanisms, demonstrating significant efficacy in numerous pre-clinical models and a favorable safety profile in toxicology studies, which lays a solid foundation for its clinical application success.
- Market Opportunity: Patient enrollment in the ongoing CheMo4METPANC Phase 2b clinical trial for metastatic pancreatic cancer has accelerated, with BioLineRx anticipating an interim analysis in 2026, further validating its therapeutic potential in high-need tumor types and creating sustained value for the company.
- Financial Update: BioLineRx's 2025 fiscal year report indicates ongoing losses; however, the company is enhancing financial flexibility through capital financing and equity issuance, providing necessary funding for the development of GLIX1 and other candidates, ensuring continued growth in the competitive biopharmaceutical market.
See More
BioLineRx to Initiate GLIX1 Clinical Trial for Glioblastoma
- Clinical Trial Progress: BioLineRx is on track to initiate a Phase 1/2a clinical trial of GLIX1 for glioblastoma by the end of this month, targeting DNA damage response mechanisms, which could address unmet needs in cancer treatment and enhance the company's competitive edge in oncology.
- Enhanced Patent Protection: The company has received a Notice of Allowance from the USPTO for a key patent covering GLIX1 in 90% of cancer types, ensuring its development beyond glioblastoma and strengthening its market position, with patent protection expected to last until 2040.
- Strong Financial Position: As of December 31, 2025, BioLineRx reported $20.9 million in cash and cash equivalents, sufficient to fund operations into the first half of 2027, indicating robust financial health that supports ongoing R&D initiatives.
- Accelerated Collaborative Research: Enrollment in the CheMo4METPANC Phase 2b clinical trial for metastatic pancreatic cancer has accelerated, with an interim analysis expected in 2026, reflecting the company's proactive approach in developing new treatment options for patients in need.
See More
BioLineRx to Announce FY Earnings on March 23
- Earnings Announcement Date: BioLineRx is set to release its financial results on March 23 before the market opens, with investors keenly awaiting performance metrics to gauge the company's future growth potential.
- Expected Financial Metrics: The consensus estimates project an EPS of -$0.77 and revenue of $1.48 million, which will provide critical insights into the company's financial health.
- Historical Performance Review: Over the past two years, BioLineRx has only beaten EPS estimates 25% of the time and revenue estimates 50% of the time, indicating uncertainty in the company's financial performance.
- Market Reaction Expectations: Investor reactions to the upcoming earnings report will directly influence BioLineRx's stock price movements, particularly given the company's historical performance has not consistently exceeded expectations.
See More
BioLineRx to Release Financial Results on March 23, 2026
- Earnings Release Schedule: BioLineRx will announce its audited financial results for the year ending December 31, 2025, on March 23, 2026, before U.S. markets open, providing investors with crucial insights into the company's financial health.
- Conference Call Details: The company will host a conference call at 8:30 a.m. EDT, featuring remarks from CEO Philip Serlin, allowing investors to engage directly with management through dial-in options at +1-888-281-1167 (U.S.) or +972-3-918-0685 (international).
- Clinical Trial Progress: BioLineRx's lead development asset, GLIX1, is expected to initiate a Phase 1/2a clinical trial in Q1 2026, targeting DNA damage response in glioblastoma and other solid tumors, showcasing the company's ongoing innovation in oncology treatments.
- Product Commercialization Status: The company's first approved product, APHEXDA® (motixafortide), is indicated for stem cell mobilization in multiple myeloma in the U.S. and is being commercialized globally by Ayrmid Ltd., indicating the company's gradual market expansion and collaboration potential.
See More
